Vertex Pharmaceuticals Incorporated (VRTX)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for VRTX is $569.95, 14.0% above the last close of $499.74 on Oct 16, 2026; targets range from $345.15 to $665.00. Rating consensus: Buy.
Snapshot
- P/E29.1x
- P/E vs sector+3.3%
- P/E vs own+3.3%
- Target upside+14.0%
- ConsensusBuy
- Market cap$127B
- FCF yield+3.0%
- InsidersNone in 90d
- Earnings in17d
- News
Why it moved
Vertex Pharmaceuticals Incorporated (VRTX) fell 1.8% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move came from the market as a whole.
2 stories on the day (30-day average 0.8).
- 3,678 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Banque Pictet & Cie SA
- Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $499.74 · +22.3% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendbullish
- Sector▲ +16.0%
- MAs20▼ 50▼ 100▲ 200▲
- Above MAs2 of 4 above
- MA20×50Death 9d ago
- RSI44
- Support-1.1%
- Resistance+2.4%
- Off 52w high-10.4%
- Off ATH-10.4%
- 52w range$499.74
- Bollingerlower half
- MACD-0.75
- ATR+2.6%
- Volume1.2x
Analyst price targets
18 firms with a target in the last 12 months · last close $499.74 · as of Oct 16, 2026
Strong buy 6 · Buy 20 · Hold 5 · Sell 1 · Strong sell 1
Revenue and free cash flow
Q2 FY2026: Revenue +12.5% year over year, free cash flow 30.4% of revenue, operating margin 37.4%.
| Q2 FY2026 | Jun 30, 2026 | $3.33B | 4.31 | $1.01B | 85.3% | 37.4% | 33.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.99B | 4.02 | $1.29B | 86.8% | 38.1% | 34.5% |
| Q4 FY2025 | Dec 31, 2025 | $3.23B | 4.65 | $349M | 85.6% | 40.3% | 36.9% |
| Q3 FY2025 | Sep 30, 2025 | $3.08B | 4.20 | $1.14B | 86.5% | 38.6% | 35.2% |
| Q2 FY2025 | Jun 30, 2025 | $2.96B | 3.99 | $927M | 86.3% | 38.8% | 34.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.77B | 2.49 | $778M | 86.9% | 22.7% | 23.3% |
| Q4 FY2024 | Dec 31, 2024 | $2.91B | 3.50 | $492M | 85.5% | 35.2% | 31.4% |
| Q3 FY2024 | Sep 30, 2024 | $2.77B | 4.01 | $1.3B | 85.8% | 40.3% | 37.7% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 | | $499.74 | -1.8% | -10.4% | +14.0% | 29.1 | $127B | |
| 2 |  | $59.75 | -1.4% | -11.3% | +9.4% | 13.2 | $122B | |
| 3 |  | $94.75 | -0.7% | -7.1% | +4.0% | 23.3 | $121B | |
| 4 |  | $218.01 | -7.8% | -7.8% | -25.0% | — | $87.04B | |
| 5 |  | $790.74 | -0.7% | -7.2% | +8.7% | 19.6 | $81.41B | |
| 6 |  | $231.83 | -0.9% | -52.8% | +61.5% | 39.2 | $31.02B | |
| 7 |  | $113.07 | -0.2% | -13.0% | +13.6% | 14.4 | $22.92B | |
| 8 |  | $72.57 | +0.1% | -0.1% | -7.0% | 62.6 | $11.38B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.